Related Experiment Video
Updated: Nov 10, 2025
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
Integrin α10-Antibodies Reduce Glioblastoma Tumor Growth and Cell Migration
Katarzyna Chmielarska Masoumi1, Xiaoli Huang1, Wondossen Sime2
1Xintela AB, Medicon Village, Scheeletorget 1, SE-223 81 Lund, Sweden.
Abstract:
Glioblastoma (GB) is the most common and the most aggressive form of brain tumor in adults, which currently lacks efficient treatment strategies. In this study, we investigated the therapeutic effect of function-blocking antibodies targeting integrin α10β1 on patient-derived-GB cell lines in vitro and in vivo. The in vitro studies demonstrated significant inhibiting effects of the integrin α10 antibodies on the adhesion, migration, proliferation, and sphere formation of GB cells. In a xenograft mouse model, the effect of the antibodies on tumor growth was investigated in luciferase-labeled and subcutaneously implanted GB cells. As demonstrated by in vivo imaging analysis and caliper measurements, the integrin α10-antibodies significantly suppressed GB tumor growth compared to control antibodies. Immunohistochemical analysis of the GB tumors showed lower expression of the proliferation marker Ki67 and an increased expression of cleaved caspase-3 after treatment with integrin α10 antibodies, further supporting a therapeutic effect. Our results suggest that function-blocking antibody targeting integrin α10β1 is a promising therapeutic strategy for the treatment of glioblastoma.
Insights
Function-blocking antibodies targeting integrin α10β1 significantly inhibited glioblastoma (GB) cell growth and tumor progression in preclinical models. This antibody therapy shows promise for treating aggressive brain tumors.
Area of Science:
- Oncology
- Immunology
- Cell Biology
Background:
- Glioblastoma (GB) is an aggressive adult brain tumor with limited treatment options.
- Integrin α10β1 is implicated in cancer cell behavior and presents a potential therapeutic target.
Purpose of the Study:
- To evaluate the therapeutic efficacy of function-blocking antibodies against integrin α10β1 in glioblastoma.
- To assess the impact of these antibodies on glioblastoma cell functions and tumor growth in vitro and in vivo.
Main Methods:
- In vitro studies using patient-derived glioblastoma cell lines to assess adhesion, migration, proliferation, and sphere formation.
- In vivo studies using a xenograft mouse model with luciferase-labeled glioblastoma cells.
- In vivo imaging, caliper measurements, and immunohistochemical analysis (Ki67, cleaved caspase-3) to evaluate tumor growth and therapeutic effects.
Main Results:
- Integrin α10β1 antibodies significantly inhibited glioblastoma cell adhesion, migration, proliferation, and sphere formation in vitro.
- In vivo, these antibodies markedly suppressed glioblastoma tumor growth in a xenograft mouse model.
- Immunohistochemistry revealed reduced proliferation (Ki67) and increased apoptosis (cleaved caspase-3) in tumors treated with integrin α10β1 antibodies.
Conclusions:
- Function-blocking antibodies targeting integrin α10β1 demonstrate significant therapeutic potential against glioblastoma.
- This antibody-based approach offers a promising new strategy for glioblastoma treatment.
Related Concept Videos
01:17Intracellular Signaling Affects Focal Adhesions
Some...
01:15Activation of Integrins
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
01:10Integrins
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...